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The delivery of therapeutics to the central nervous system (CNS) is
not effective for greater than 98% of small molecules and for
nearly 100% of large molecules, despite the presence of an
immense network of cerebral vasculature1. The lack of effective-
ness is due to the presence of the blood–brain barrier (BBB),
which prevents most foreign substances, even many beneﬁcial
therapeutics, from entering the brain from the circulating blood.
Although some small molecule, peptide and protein therapeutics
given systemically reach the brain parenchyma by crossing the
BBB, high systemic doses are generally needed to achieve
therapeutic levels, resulting in adverse effects2. Therapeutics can
be introduced directly into the CNS by intracerebroventricular or
intraparenchymal injections; however, for multiple dosing regi-
mens, both delivery methods are invasive, risky, and expensive
techniques requiring surgical expertise. Additional limitations to
the utility of these methods are inadequate CNS exposure due to
slow diffusion from the injection site and rapid turnover of the
cerebrospinal ﬂuid (CSF). Intranasal delivery has come to the
forefront as an alternative to invasive delivery methods to bypass
the BBB and rapidly target therapeutics directly to the CNS. This
delivery method utilizes pathways along olfactory and trigeminal
nerves innervating the nasal passages3–5.
Nimodipine is a dihydropyridine calcium channel blocker used in
the treatment of cerebrovascular spasm and senile dementia. The
major problem associated with nimodipine is extensive ﬁrst pass
metabolism, low solubility and low oral bioavailability (5%–10%)
in humans, thus accounting for low brain concentration. Nimodipine
is a P-glycoprotein substrate, another characteristic contributing to
its low oral bioavailability. P-glycoprotein-mediated drug efﬂux
may also contribute to low brain drug levels. Intranasal nimodipine
administration has been shown to achieve higher drug levels in
brain as compared to the oral route6. The problem of low solubility
of nimodipine was addressed by using 2-hydroxypropyl-β-cyclo-
dextrin or diheptanoyl phosphatidylcholine as solubilizers to prepare
water-soluble dosage forms of nimodipine. However, these
approaches could not be used for intranasal delivery, since the
therapeutic dose of nimodipine for intravenous (i.v.) administration
is 0.5–2 mg7–9, and the effective nasal delivery volume in human is
r400 mL (200 mL per nostril). This problem was resolved by
developing a nimodipine-loaded microemulsion for intranasal
delivery which achieved higher brain concentrations as compared
to the oral route10. Microemulsion-based delivery systems have
many characteristics which make them suitable for intranasal drug
delivery. These include ease of preparation (due to spontaneous
formation), thermodynamic stability, transparent and elegant appear-
ance, increased drug loading, enhanced penetration through the
biological membranes, increased bioavailability11,12, and less inter-
and intra-individual variability in drug pharmacokinetics13.
The aim of the present study was to develop an in situ gelling
mucoadhesive microemulsion system for intranasal delivery of
nimodipine. This formulation was designed to attain higher levels
of nimodipine in the brain, overcome P-glycoprotein mediateddrug efﬂux, reduce mucociliary drug clearance, and prolong drug
release from the formulation. A thermosensitive polymer was used
which converted from solution to gel upon intranasal administra-
tion. The bioadhesive property of the gel permits a prolonged
adherence to the nasal mucosa, resulting in sustained drug release
from the matrix. The new formulation was then characterized for
various physicochemical parameters. A pharmacokinetic study
of in situ gelling mucoadhesive microemulsion containing nimo-
dipine was performed in rats to determine the concentration of
nimodipine in the brain, plasma and nasal mucosa following
intranasal administration. Results were compared with the phar-
macokinetic proﬁle of nimodipine achieved with suspension and
microemulsion preparations.2. Materials and methods
2.1. Materials
Nimodipine and nifedipine were obtained as a gift sample from
Astron Research Ltd., Ahmedabad, India. Carbopol 934 P was
obtained as a gift sample from Lubrizol Advanced Materials India
Pvt. Ltd., Mumbai, India. Capmul MCM was purchased from
Abitec Corporation, Janesville WI. Labraﬁl M 1944 CS, Peceol,
Maisine 35-1, Labrasol and Transcutol P were purchased from
Gattefosse, France. PEG 400, Pluronic F 68 and 127 were
purchased from Sigma-Aldrich Co., MO, USA. Tween 80 was
obtained from S.D. Fine Chemicals, Mumbai, India. Sodium
hydroxide and potassium dihydrogen ortho-phosphate (analytical
grade) were obtained from Qualigen Fine Chemicals, Mumbai,
India. All the solvents and chemicals used for the study were of
chromatographic grade and purchased from Qualigen Fine Che-
micals, Mumbai, India. Heparin was purchased from Biological
E. Ltd., Hyderabad, India. Heparinised capillaries were purchased
from Himedia, Mumbai, India. Deionized water for HPLC was
prepared in-house using a Milli-Q water puriﬁer system (Millipore
Elix, Germany).
2.2. Formulation development
2.2.1. Estimation of solubility of nimodipine in oils, surfactants
and co-surfactants
The solubility of nimodipine was studied in various oils, surfac-
tants and co-surfactants which were selected according to their
applicability in nasal formulations. The oils screened for this study
include Maisine 35-1, Labraﬁl 1944 CS, Capmul MCM, and
Peceol. Labrasol and Tween 80 were screened as surfactants and
PEG-400 and Transcutol P were screened as co-surfactants.
The solubility of nimodipine in various oils, surfactants and co-
surfactants was determined by adding an excess of nimodipine to a
cap vial containing each of the selected vehicle (2 mL)14. The
mixture was heated in a 40 1C water bath to facilitate the
solubilization using a vortex mixer after sealing the vials. Mixtures
were allowed to equilibrate in a shaker (Remi Equipments, India)
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10 min after the equilibrium was achieved. The samples (500 mL
of supernatant) were withdrawn and the content of nimodipine was
quantiﬁed by UV–visible spectrophotometer (Systronics 2201,
India) at 238 nm after dilution with methanol.
2.2.2. Preparation of phase diagrams
The pseudoternary phase diagrams of oil, surfactant, co-surfactant
and water were constructed using a water titration method to
obtain the concentrations of components. Surfactant was blended
with co-surfactant in ﬁxed weight ratios (1:1, 2:1 and 3:1).
Aliquots of each surfactant and co-surfactant mixture (Smix) were
then mixed with oil at room temperature (25 1C). For each, phase
diagram, the ratio of oil to the Smix was varied as 9:1, 8:2, 7:3, 6:4,
5:5, 4:6, 3:7, 2:8, 1:9 (w/w)10. Water was added drop-wise to each
oil–Smix mixture under vigorous stirring and then kept aside. After
equilibrium, the samples were visually checked and determined as
being clear microemulsions, or emulsions, or gels. Phase diagrams
were constructed using Triplot software version 4.1. Once the
microemulsion region was identiﬁed, nimodipine microemulsion
was prepared by dissolving nimodipine into the oil–Smix mixture,
followed by addition of required amount of water with stirring.
The resultant microemulsions were tightly stored at ambient
temperature, and their physical stability was measured by obser-
ving periodically the occurrence of phase separation.
2.2.3. Screening of mucoadhesive and gelling excipients
Various mucoadhesive and gelling excipients were screened to
ascertain thermoresponsive behavior of gelling and mucoadhesive
excipients. Pluronic F 127 and Pluronic F 68 were screened as
gelling agents while Carbopol 934 P, chitosan, sodium alginate
and sodium CMC were screened as mucoadhesive agents. Ther-
moreversible gels of Pluronic F 127 and Pluronic F 68 were
prepared by a cold method in which Pluronic was solubilized in
distilled water and phosphate buffer (pH 6.7 and 7.4, individually)
at 4 1C. The solutions were kept at 4 1C until they became clear.
The temperature was increased gradually from 15 to 40 1C to
assess gelling behavior, visually. The gelling nature was evaluated
on a small volume of sample (500 mL). Similarly, the dispersions
were prepared with varying concentrations of mucoadhesive
agents15. Samples were weighed accurately, soaked in water,
and kept aside at room temperature overnight. The resulting
samples were then examined visually for gelling behavior at room
temperature.
2.2.4. Preparation of in situ gelling mucoadhesive
microemulsion
The in situ gelling mucoadhesive microemulsion was prepared by
dissolving nimodipine in oil, followed by addition of surfactant–
cosurfactant (Smix) mixture. Mucoadhesive and gelling excipients
were dissolved in aqueous phase. The ﬁnal drug–oil–Smix mixture
was then titrated with the aqueous phase14 to obtain mucoadhesive
microemulsion and stored at refrigerated temperature (4 1C) for
further studies. Microemulsion of nimodipine was also prepared in
similar manner without addition of mucoadhesive polymer.
2.3. Evaluation of formulation
2.3.1. Physicochemical evaluation
2.3.1.1. Photon correlation spectroscopy Photon correlation spec-
troscopy (PCS) was employed to determine the mean particle size(PCS diameter) and size distribution (poly-dispersity index, PDI). The
particle size of the optimized microemulsion was determined by light
scattering based on laser diffraction using Malvern zeta-sizer ZS90
(Malvern Instruments, Inc., UK) after suitable dilution. The analysis
was carried out for 2 min at room temperature at angle of detection of
901. The apparatus consisted of a He–Ne laser (5 mW) and a sample
holding cell of 5 mL capacity.
2.3.1.2. Zeta potential The measurement of zeta potential has
become inextricably connected with the characterization of colloidal
dispersions, as this parameter is highly useful for the assessment of
the physical stability of colloidal dispersions. Zeta potential was
measured using Malvern Zetasizer ZS 90 (Malvern Instruments, UK).
2.3.1.3. pH, viscosity and gelling temperature The pH of the
developed formulation was measured using pH meter (LI-120,
Eutech Instrument, Singapore). The rheological property of in situ
gelling mucoadhesive microemulsion was measured by Ostwalds
Viscometer (Brookeﬁeld Instrument, UK). The gelling temperature
was measured by keeping the formulation on a magnetic stirrer
with heater. The temperature was gradually increased and the
viscosity was also measured simultaneously. The temperature at
which the gel formation occurred with desired viscosity was
recorded as the gelling temperature.
2.3.1.4. Percentage transmittance The prepared formulation was
diluted 10 times with continuous media and acetate buffer and the
effect of dilution on globule size, percentage transmittance and
phase separation was checked. The percentage transmittance of the
developed formulation was measured at 650 nm using
UV–visible spectrophotometer keeping distilled water as a blank10.
2.3.1.5. Stability assessment The shelf-life stability of in situ
gelling mucoadhesive microemulsion system, both as a function of
time and storage temperature was routinely checked by visual
inspection of the samples initially on a daily and later on a weekly
basis. Stable systems were identiﬁed as those free of any physical
change, such as phase separation, ﬂocculation or precipitation.
Particle size of the system upon storage was also monitored to
assess system stability in terms of drastic changes in the mean
particle size due to coalescence or aggregation. Stability was
monitored at 4 1C, ambient temperature, 37 1C and 50 1C.
2.3.2. Entrapment efﬁciency and drug loading
The entrapment efﬁciency of nimodipine loaded microemulsion
was determined by a centrifugation method. Brieﬂy, 10 mL
0.1 mol/L HCl was added into drug-loaded microemulsion,
followed by centrifugation for 10 min at 20,000 rpm. The super-
natant was separated and the pellets were washed thrice with
distilled water. The free drug concentration was determined by
UV–visible spectrophotometric analysis at 238 nm. The entrap-
ment efﬁciency and drug loading of nimodipine microemulsion
were calculated as per equations given below. All the measure-
ments were performed in triplicate.
Entrapment efficiency ð%Þ ¼ ½ðWa–W sÞ=Wa  100 ð1Þ
Drug loading ð%Þ ¼ ½ðWa–W sÞ=ðWa–W s þW lÞ  100 ð2Þ
where Wa is the amount of drug added to formulation, Ws is the
amount of free drug, and Wl is the weight of oil phase.
2.3.3. Estimation of mucoadhesive strength
The mucoadhesive strength was determined for the optimized
formulation using Brookﬁelds texture analyzer-QTS where one
end of texture analyzer was connected to 34 mm probe, to which
907.46 mm2 goat nasal mucosa (obtained from local slaughter
R. Pathak et al.154house) was appended16. The other end contained 40 mL of in situ
gelling mucoadhesive microemulsion. Nasal mucosa was exposed
to formulation for about 30 s and then allowed to detach to obtain
load versus time behavior of the formulation.
2.3.4. In vitro drug release
The drug release from in situ gelling mucoadhesive microemul-
sion, microemulsion and suspension was estimated. In vitro drug
release studies were performed using a Franz diffusion cell
(12.5 mL) at 3770.5 1C for 8 h with stirring at 400 rpm. Dialysis
membrane (cellulose membrane, molecular weight cut-off between
12,000 and 14,000 Da, pore size 2.4 nm) was presoaked in
simulated nasal ﬂuid for 15 min. Presoaked membrane was
mounted between the donor and receiver compartment of the
diffusion cell (cross sectional area 3.14 cm2) and clamped into
position. The mucoadhesive microemulsion (0.5 mL) was uni-
formly spread over the membrane from the donor compartment
side. The reservoir ﬂuid (simulated nasal ﬂuid) was maintained in
the receiver compartment at 3770.5 1C at the constant volume of
12.5 mL. Samples (1 mL) were withdrawn from the receiver
compartment after every hour and replaced by an equivalent
amount of temperature-equilibrated fresh media. The samples were
analyzed, after adequate dilutions, at 238 nm on UV–visible
spectrophotometer. The same procedure was repeated for nimodi-
pine microemulsion and suspension.
2.3.5. Ex vivo drug permeation studies
The fresh nasal mucosa was carefully excised from the nasal cavity of
goat obtained from the local slaughter house. Freshly excised goat
nasal mucosa was dipped immediately in phosphate buffer (pH 6.4).
Cartilages were removed properly and the mucosal membrane was
isolated and washed with phosphate buffer17. The mucosal preparation
was mounted on the receptor compartment of a Franz diffusion cell
displaying a permeation area of 3.14 cm2. Simulated nasal ﬂuid
(12.5 mL) was added to the receptor compartment. The mucosal
preparation was mounted on the diffusion cell with the mucosal and
serosal sides facing the donor and receiver phases, respectively. A
small teﬂon coated magnetic bead was placed in the receptor
compartment for stirring the media. The donor and receptor compart-
ments were securely closed with a stainless steel clip. The tissue
sample was pre-incubated for 20 min, maintaining temperature at
37 1C. After a pre-incubation time of 20 min, in situ gelling
mucoadhesive microemulsion was added to the donor compartment
on the outer surface of the nasal mucosa. The permeation study was
carried out for 8 h. The aliquots were withdrawn at 15, 30 min, 1, 2, 3,
4, 5, 6 and 7 h, diluted appropriately with simulated nasal ﬂuid, and
assayed for drug concentration using HPLC at 358 nm. The chromato-
graphic conditions for HPLC analysis of nimodipine were the same as
that for plasma and brain tissue analysis (see analytical method below).
The percentage drug permeation was calculated from the calibration
curve of nimodipine prepared in simulated nasal ﬂuid. The same
procedure was repeated for nimodipine microemulsion and suspension.
2.3.6. Histological evaluation of nasal mucosa
Histological studies were done on excised nasal mucosa from rats
(n¼6) dosed with in situ gelling mucoadhesive microemulsion of
nimodipine, intranasally. The animals were euthanized and mucosa
was collected from all the animals 24 h post-dose. Sections (5 mm)
of the nasal mucosa were collected using a rotary microtome
(Model 0126, Yorco, India), followed by staining with haematox-
ylin and eosin. Treated and untreated specimens were comparedfor histological appearance with an Olympus IX51 optical micro-
scope (Olympus Optical Co., Ltd., Tokyo, Japan). Photographs
were taken with an Olympus TL4 camera.2.3.7. Nasal absorption and brain distribution studies
2.3.7.1. Animal studies Male Sprague-Dawley rats weighing
250–280 g were obtained from the animal house of B.V. Patel
PERD Centre, Ahmedabad. Animal housing and handling was
performed in accordance with Good Laboratory Practice (GLP)
mentioned in CPCSEA guidelines. Animal house is registered with
the Committee for the Purpose of Control and Supervision of
Experiments on Animals, Ministry of Social Justice and Empow-
erment, Government of India, vide registration No. 1661/PO/a/12/
CPCSEA, dated 21/11/2012. All experimental protocols were
reviewed and accepted by the Institutional Animal Ethics Com-
mittee prior to initiation of the experiment. The animals were
housed in polypropylene cages (3 animal/cage) and placed in the
experimental room where they were allowed to acclimatize for a
week before experiment. A 10% air exhaust conditioning unit was
maintained along with a relative humidity of 6075% and a
temperature of 2573 1C in the animal house facility. A light/dark
cycle of 10 h/14 h was also regulated for the experimental animals.
Amrut certiﬁed rodent diet (Maharashtra Chakan Oil Mill Ltd.)
and tap water (boiling hot water cooled to room temperature) were
provided ad libitum to the experimental animals.
The animals were kept in fasting condition overnight before the
experiment commenced. Animals were divided in three groups.
The 1st group was dosed with nimodipine suspension, 2nd group
with previously reported nimodipine microemulsion10, and 3rd
with in situ gelling mucoadhesive microemulsion of nimodipine,
intranasally. For the intranasal administration, 25–40 mL of the
nasal formulations (concentration: 7.5 mg/mL for in situ gelling
mucoadhesive microemulsion and nimodipine suspension and
6.4 mg/mL for reported nimodipine microemulsion) was adminis-
tered via a polyethylene 10 tube attached to a microlitre syringe
inserted 1 cm into each nostril of rat at a dose of 2 mg/kg. The
blood samples of 0.5 mL were withdrawn from each rat through
retro-orbital sinus at 0, 5, 15, 30 min, 1, 2, 4 and 6 h post-dose,
collected into heparinized microcentrifuge tubes and centrifuged at
4000 rpm for 7 min at 4 1C. The animals were decapitated
immediately after the blood collection and brain was excised at
the above mentioned time points. Each brain tissue was quickly
rinsed with saline and blotted up with ﬁlter paper to get rid of
blood-taint and macroscopic blood vessels as much as possible.
After weighing, the brain tissue samples were homogenized with
1 mL of saline at 10,000 rpm for 1 min over ice using a tissue
homogenizer (Kinematica, Switzerland). The nasal mucosa was
excised and homogenized in the similar process as that of brain
samples. All the samples were kept frozen at 80 1C prior to
HPLC analysis.
2.3.7.2. Analytical procedures Nimodipine in brain tissue, plasma
and nasal mucosa was assayed using a modiﬁed reported HPLC
method10. To 200 mL brain tissue and nasal mucosa homogenates or
100 mL of plasma, 25 mL of nifedipine (20 mg/mL, internal standard)
and 0.1 mL 1 mol/L NaOH were added and extracted with 1 mL
extraction solvent (n-hexane/diethylether¼50:50) by vortexing for
2 min. The samples were then centrifuged at 10,000 rpm for 10 min
at 4 1C for tissue samples and at 2000 rpm for 10 min at 4 1C for
plasma samples. This was followed by separation and transfer of the
organic layer into evaporating tubes. The organic layer was evapo-
rated under gentle stream of nitrogen till dryness. The samples were
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onto HPLC system consisting of a PU-980 HPLC pump (Jasco,
Hachioji, Tokyo, Japan) and UV-975 UV–visible detector (Jasco,
Hachioji, Tokyo, Japan) set at 358 nm and a manual injection port.
The data were analyzed using Borwin software version 1.3.
Chromatographic separation was achieved using a Purospher
STAR column (250 mm 4.6 mm, 5 mm) maintained at room
temperature. The mobile phase consisted of water:methanol:
acetonitrile (25:35:40, v/v/v). The mobile phase was prepared
daily and degassed before use. The ﬂow-rate was maintained at
1.0 mL/min. Samples were quantiﬁed by determining the response
(Peak areaDrug/Peak areaIS).
Calibration curves of nimodipine were prepared with plasma and
respective tissues spiked with known amounts of the drug utilizing
its HPLC peak area ratio to the internal standard. The linear range
of nimodipine was 10–1000 ng/mL for plasma and tissue samples.
The calibration curves were obtained by least square linear
regression analysis using weight scheme as 1/c (c¼concentration)
with Borwin software version 1.3. All operations except data
evaluation were carried out under thorough light shelter as
nimodipine is sensitive to light-induced degradation18.
2.3.7.3. Data analysis The maximum plasma concentration (Cmax)
and the time to reach the maximum concentration (Tmax) were directly
determined from the plasma concentration versus time curves. The
area under the curve from 0 to t (AUC0–t) was calculated following
the linear trapezoidal rule by summing the area from 0 to t h.
2.3.7.4. Statistical analysis Statistical data analysis was per-
formed using Graphpad Prism software where one-way analysis
of variance followed by Bonferroni's test was applied and Pr0.05
was considered as the minimal level of signiﬁcance unless
indicated otherwise.
3. Results and discussion
3.1. Formulation development
3.1.1. Estimation of solubility of nimodipine in oils, surfactants
and co-surfactants
Nimodipine exhibited good solubility in Capmul MCM (14.0
mg/mL) as compared to other oils. The solubility was better inFigure 1 Solubility of nimodipine in different oils, surfactantsLabrasol (28.20 mg/mL) and Transcutol P (47.54 mg/mL) which
were chosen as surfactant and co-surfactant, respectively. The high
solubility of nimodipine in Transcutol P reinforces its ability as a
powerful solubilizing agent which is also seen for many other
drugs. Fig. 1 shows the graphical representation of the solubility of
nimodipine.
3.1.2. Preparation of phase diagrams
The selection of oils, surfactants and co-surfactants and the
surfactant/co-surfactant ratios plays an important role in the
formulation of microemulsion. The formulation of nimodipine
microemulsion was optimized by evaluating the microemulsion
regions using pseudoternary phase diagrams. A pseudoternary
phase diagram of the investigated quaternary system water/
Labrasol/Transcutol/Capmul MCM is presented in Fig. 2 and it
shows phase diagrams with different S/CoS. The shaded areas
indicate the clear o/w microemulsion system. The phase study
revealed that the maximum proportion of oil was incorporated in
the microemulsion system when the surfactant/co-surfactant ratio
was 2:1.
3.1.3. Screening of mucoadhesive and gelling excipients
Various mucoadhesive and gelling excipients were selected for
their use in development of in situ gelling microemulsions.
Thermoresponsive behavior was observed for Pluronics. Based
on visual observations, gelling characteristics were satisfactory for
both the grades of Pluronics. A blend of Pluronics showed
satisfactory thermoreversible characteristics and was therefore
used in the microemulsion. Gelling properties of various concen-
trations of Carbopol 934 P were assessed similarly. Carbopol 934
P with 0.3% (w/w) showed good gelling behavior and was selected
as mucoadhesive excipient in the formulation. Table 1 shows
gelling behavior of polymers at varying pH and temperatures.
3.1.4. Preparation of in situ gelling mucoadhesive
microemulsion
The in situ gelling mucoadhesive microemulsion was optimized
based on globule size and zeta potential. The optimized formulation,
shown in Table 2, had the minimum particle size and maximum
entrapment efﬁciency. The evaluated parameters are shown inand cosurfactants. Data are expressed as mean7SD (n¼6).
Table 1 Gelling behavior of polymers at varying pH values and temperatures.
Excipients Gelling at
40 1C
Gelling at
room
temperature
Gelling in
phosphate buffer
Gelling at
small
scale
(500 mL)pH 6.7 pH 7.4
Pluronic F 127 þ NA þ þ þ
Pluronic F 68 – NA þ þ þ
Combination of Pluronics (F 127 20% w/w and F 68 8% w/w) þþ NA þþ þþ þ
Carbopol 934 P concentration
(0.3% w/v)
NA þ þ þ þ
Carbopol 934 P concentration
(0.5% w/v)
NA þ þ þ þ
Carbopol 934 P concentration
(1.0% w/v)
NA Excessive
gelling
and turbid
formulation
Excessive
gelling
Excessive
gelling
þ
Combination of Pluronics (F 127 20% w/w and F 68 8% w/w) and
Carbopol 934 P concentration (0.3% w/v)
þ þ þ þ þ
–: Absence of gelling behavior; þ: gelling at the surface; þþ: satisfactory and thermoreversible behavior. NA: Not applicable.
Table 2 Excipient composition of optimized in situ gelling
mucoadhesive microemulsion.
Figure 2 Pseudoternary phase diagram with varying ratios of the investigated quaternary system water/Labrasol/Transcutol/capmul MCM with
(a) Smix in the ratio of 1:1 (b) Smix in the ratio of 2:1 and (c) Smix in the ratio of 3:1. The shaded areas indicate the clear o/w microemulsion system.
R. Pathak et al.156Table 3. Fig. 3 shows the graph of particle size distribution. This
optimized formulation was used for in vitro, ex vivo and in vivo
studies.Role/category Name % w/w
Oil Capmul MCM 4
Surfactant Labrasol 20
Co-surfactant Transcutol P 10
Aqueous phase Water 66
Mucoadhesive Carbopol 934P 0.3
Gelling excipient 1 Pluronic F127 20
Gelling excipient 2 Pluronic F 68 83.2. Evaluation of formulation
3.2.1. Physicochemical evaluation
The physicochemical characteristics of the optimized in situ
gelling mucoadhesive microemulsion are shown in Table 3. The
pH was found to be 6.7, which lies within the pH range of the
nasal cavity (5.5–7.5). The formulation has low viscosity and
thus makes it pourable for nasal administration. The system
Figure 3 Representation of the obtained data for average particle
size of in situ gelling mucoadhesive microemulsion.
Table 3 Stability of microemulsion and in situ gelling mucoadhesive microemulsion after 30 days.
Parameters Microemulsion Mucoadhesive microemulsion
Initial After 30 days Initial After 30 days
Globule size (nm) 15074.5 17076.5 25076.7 28079.7
Zeta potential (mV) 1570.3 1470.3 1570.45 1370.45
pH – – 6.770.2 6.770.2
Viscosity (cP) 27.570.3 26.570.4 35.570.7 36.570.7
Gelling temperature (1C) – – 28–32 28–32
Transmittance (%) 9072 8874 8075 7873
Drug loading (%) 7072 6972 6872 6572
Data are expressed as mean7SD, n¼6.
Table 4 Mucoadhesive strengths of individual polymers and
developed formulation.
Time
(s)
Mucoadhesive strength (g)
Carbopol
934 P
Pluronic
127
Pluronic
68
Developed
formulation
30 1972.4 1872.7 1471.8 2071.6
60 1371.9 1572.2 1271.5 1371.4
120 1071.5 1071.2 870.9 370.2
Data are expressed as mean7SD, n¼6.
Figure 4 In vitro release proﬁle of nimodipine from different
formulations. Data are expressed as mean7SD (n¼6).
Intranasal delivery system for nimodipine 157demonstrated good transparency (480%) with particle size in the
nanometer range. The prepared formulation was physically stable
for sustained periods with or without addition of nimodipine; no
occurrence of phase separation or signiﬁcant changes in particle
size was observed. The stability of the formulation was further
reinforced by the high zeta potential value. The results of the study
inferred that solubility of nimodipine was enhanced in microemul-
sion based systems. The adhesiveness of the individual polymers
and developed formulation are summarized in Table 4. It was
observed that the mucoadhesive strength of the ﬁnal formulation
was more or less similar to that of the Carbopol 934 P. These
results indicate that the formulation possessed sufﬁcient mucoad-
hesiveness and to adhere to nasal mucosa upon administration.3.2.2. In vitro drug release behavior
The results of drug release studies from in situ gelling mucoadhe-
sive microemulsion are shown in Fig. 4. The drug release behavior
was studied in simulated nasal ﬂuid. Incorporation of drug in
microemulsion-based system improved drug solubilization andin vitro release, as compared to drug suspension. In situ gelling
mucoadhesive microemulsion based system showed a high initial
burst, due to the presence of Pluronic. Pluronic, a surfactant at low
concentration, facilitates solubilization and higher drug release.
The drug release at later stages was hampered due to extensive
cross linking of Pluronic at higher temperature (temperature-
dependent gelling). The presence of mucoadhesive agent (Carbo-
pol 934 P) might have also restricted the drug release14. The higher
initial burst release is desirable in case of immediate therapeutic
intervention as in the case of patients suffering from stroke.
3.2.3. Ex vivo permeation studies
The permeation of nimodipine in situ gelling mucoadhesive
microemulsion, microemulsion and suspension across the nasal
mucosa is shown in Fig. 5. The drug suspension in water showed
lowest permeability. Drug permeation improved in microemulsion
based system, which may be attributed to the presence of
surfactants and co-surfactants, which helps in solubilization. The
higher permeation may be due to the transcellular uptake, high
solubilization capacity as well as the potential for enhanced
absorption of the microemulsion19. In situ gelling mucoadhesive
microemulsion showed a high initial burst release, which may be
due to the presence of Pluronic. Carbopol 934 P might have also
contributed to the enhancement of drug absorption; this may be
due to the opening of tight junctions, thereby facilitating transport
of drugs via paracellular pathway14.
R. Pathak et al.1583.2.4. Histological evaluation of nasal mucosa
Microscopic observations indicated that the optimized formulation
had no signiﬁcant effect on the histological appearance of mucosa.
The epithelium layer was intact, with no alterations in basalFigure 5 Ex vivo permeation study of nimodipine from different
formulations. Data are expressed as mean7SD (n¼6).
Figure 6 Histological photomicrographs of eosin–hematoxylin-
stained nasal mucosa (10 magniﬁcation). (A) Control mucosa
without application of formulation; (B) nasal mucosa after application
of nimodipine in situ gelling mucoadhesive microemulsion.
Figure 7 Concentrations of nimodipine in (a) brain, (b) nasal mucosa an
rats. Data are expressed as mean7SD (n¼6).membrane or in the superﬁcial part of sub mucosa, and no necrosis
was observed (Fig. 6). Thus the optimized formulation seemed to
be safe with respect to nasal administration.3.2.5. Nasal absorption and brain distribution studies
The intranasal route has been used for effective delivery of many
therapeutic entities to the brain, including nimodipine as a
suspension6, as well as in an o/w microemulsion system10. The
microemulsion system served as an effective delivery system for
nimodipine. However, an in situ gelling mucoadhesive micro-
emulsion system was developed for nimodipine with an approach
to achieve better residence time, reduced mucociliary clearance
and better bioavailability as compared to the reported microemul-
sion system. The concentration of nimodipine in brain, nasal
mucosa and plasma was determined after intranasal administra-
tion of nimodipine suspension, nimodipine microemulsion and
nimodipine in situ gelling mucoadhesive microemulsion. Fig. 7a–c
represents the mean brain tissue, nasal mucosa and plasma
concentration–time proﬁles of nimodipine after intranasal admin-
istration of different formulations to rats at a dose of 2 mg/kg.
Pharmacokinetic parameters of the different animal groups are
shown in Table 5. Following intranasal administration, the proﬁles
of nimodipine in brain displayed an initial absorption phase, with
maximal concentrations within 30 min, followed by a rapid decline
phase for all the three formulations. However, Cmax and AUC
values attained with in situ gelling mucoadhesive microemulsion
were signiﬁcantly higher than those from the nimodipine micro-
emulsion and nimodipine suspension treatments. The sampling
time points for brain, nasal mucosa and plasma were initially up to
6 h. However, the plasma concentration was found to increase up
to the last time point (6th hour). Based upon these results, another
study was performed to develop an extended plasma proﬁle of
nimodipine upon intranasal administration of the three formula-
tions. The blood sampling points for the second study were 0, 5,
15, 30 min, 1, 2, 4, 6, 7, 8, 12 and 24 h post-dose.
Nasal absorption of nimodipine from both the microemulsion
formulations into systemic circulation exhibited sustained
release, with maximal plasma concentrations achieved at 6 h.
The maximum plasma concentration for nimodipine upon
administration as a suspension was observed at 1 h. Nimodipine
concentrations were measured in nasal mucosa with an objec-
tive to determine the amount of drug retained in nasal cavity.
The results inferred that signiﬁcant amount of drug was present
in nasal mucosa, following administration of microemulsiond (c) plasma after intranasal administration of different formulations in
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Intranasal delivery system for nimodipine 159formulations, indicating that a large fraction of drug remains at
the site of application. This may be due to incorporation of
mucoadhesive and gelling excipients. However, higher concen-
trations of nimodipine were present in the nasal mucosa of
animals dosed with nimodipine suspension, likely to be due to
the larger concentrations of the drug in suspension, not able to
cross the nasal mucosa. This was also reﬂected in the corre-
sponding low concentration in the brain and plasma of the
animals dosed with nimodipine suspension. Statistical analysis
showed a signiﬁcant difference (Pr0.05) in nimodipine con-
centrations in the plasma, brain and nasal tissue upon intranasal
administration of different formulations, inferred from AUC
values. These results were in agreement with the previous
reports indicating the existence of an alternative pathway for
brain delivery of nimodipine by formulating as o/w
microemulsion10.
Despite the potential of the nasal route for effective drug
delivery, it is associated with many disadvantages, including
mucociliary clearance, enzymatic activity, and the barrier nature
of the epithelium combined with the mucus layer. The latter is
especially problematic for the nasal absorption of high
molecular-weight and hydrophilic drugs10,20–22. Therefore, the
use of absorption enhancers and/or the design of suitable
formulations (e.g., microemulsions and mucoadhesive delivery
systems) are necessary to enhance the nasal bioavailability of
these drugs23,24. The main ﬁnding of the present study is that the
combination of the surfactant Pluronics (as an absorption
enhancer) and Carbopol 934 P (as a mucoadhesive agent) can
signiﬁcantly increase the nose-to-brain delivery of nimodipine.
While the exact mechanism of this effect has not been deter-
mined, it is known that mucoadhesive additives may improve
drug absorption by reducing the mucociliary clearance rate and
by increasing the residence time of the drug formulation in the
nasal cavity25,26. Moreover, the use of both Labrasol and Capmul
MCM (both of which are reported to inhibit P-glycoprotein
activity27,28) might also be responsible for the observed improved
bioavailability of nimodipine from the developed formulation.
Furthermore, some mucoadhesive polymer-containing systems
may directly change epithelial tight junctions and increase drug
absorption and bioavailability23,29.4. Conclusions
The microemulsion system containing 4% (w/w) Capmul MCM,
30% Labrasol/Transcutol P (2:1) and water was found to be
optimum for intranasal delivery of nimodipine. This preparation
had a higher solubility of nimodipine (up to 7.5 mg/mL), as
compared to earlier reported formulation (6.4 mg/mL10). The
incorporation of 0.3% (w/w) of Carbopol 934 P was considered
optimum for mucoadhesive microemulsion formulation. Sufﬁ-
cient gelling at physiological temperature was obtained with 20%
(w/w) Pluronic F 127 combined with 8% (w/w) Pluronic F 68.
The formulation was found to be physically stable for 3 months
at ambient conditions. In vitro and ex vivo studies showed the
drug release up to 6 h with a burst release at 30 min. The burst
release was due to incorporation of Pluronics and the prolonged
release up to 6 h was attributed to the mucoadhesives used in the
formulation. In vivo pharmacokinetic studies in rats showed a
higher brain and plasma concentrations of nimodipine from
in situ gelling mucoadhesive microemulsion as compared to
earlier reported formulation. It can be concluded from this study
R. Pathak et al.160that, this formulation strategy may be tried for effective targeting
of other therapeutic entities to CNS which are reported to have
low bioavailability and poor brain penetration.
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